Literature DB >> 10752997

Carboxypeptidase G2 rescue in delayed methotrexate elimination in renal failure.

M Mohty1, H Peyriere, C Guinet, D Hillaire-Buys, J P Blayac, J F Rossi.   

Abstract

We report here the case of a 68-year-old woman who presented severe renal failure following the first cycle of high dose methotrexate (HDMTX) for the treatment of a cerebral malignant lymphoma. Before HDMTX administration, serum creatinine value was normal and three days after HDMTX, it reached 457 micromol/L. Leucovorin rescue, hemodialysis and cholestyramine did not increase MTX clearance. Because of the persistence of renal failure, and the high risk of important hematological side-effects associated with high MTX plasma levels, the patient received carboxypeptidase G2 (CPDG2). This allowed MTX plasma levels to decrease by 80% in 15 minutes. No side effects were observed and renal function normalized rapidly. In some patients, when high-dose leucovorin associated with hemodialysis and cholestyramine are unable to restore normal MTX clearance, CPDG2 should be considered because it may represent a safe and efficient alternative for the management of MTX intoxication.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10752997     DOI: 10.3109/10428190009089446

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

1.  Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.

Authors:  Brigitte C Widemann; Frank M Balis; AeRang Kim; Matthew Boron; Nalini Jayaprakash; Aiman Shalabi; Michelle O'Brien; Michelle Eby; Diane E Cole; Robert F Murphy; Elizabeth Fox; Percy Ivy; Peter C Adamson
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

2.  Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.

Authors:  Jeffrey R Scott; Yinmei Zhou; Cheng Cheng; Deborah A Ward; Hope D Swanson; Alejandro R Molinelli; Clinton F Stewart; Fariba Navid; Sima Jeha; Mary V Relling; Kristine R Crews
Journal:  Pediatr Blood Cancer       Date:  2015-01-28       Impact factor: 3.167

3.  Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.

Authors:  Anthony M Christensen; Jennifer L Pauley; Alejandro R Molinelli; John C Panetta; Deborah A Ward; Clinton F Stewart; James M Hoffman; Scott C Howard; Ching-Hon Pui; Alberto S Pappo; Mary V Relling; Kristine R Crews
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

4.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

5.  MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase.

Authors:  Zachary L Taylor; Tomoyuki Mizuno; Nieko C Punt; Balaji Baskaran; Adriana Navarro Sainz; William Shuman; Nicholas Felicelli; Alexander A Vinks; Jesper Heldrup; Laura B Ramsey
Journal:  Clin Pharmacol Ther       Date:  2020-07-18       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.